Skip to main content

Table 1 Stratification according to risk for recurrence prior to randomization according to predefined groups and distribution of BEXIDEM and BCG among the risk groups.

From: The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

Group TNM Classification Number of Tumors BEXIDEM® BCG
A Ta Grade 1
T1 Grade 1
Single or multiple
Single
26 29
B Ta Grade 2
T1 Grade 1
T1 Grade 2
Single or multiple
Multiple
Single
26 26
C Ta Grade 3
T1 Grade 2
Single or multiple
Multiple
23 23